- Myelofibrosis (intermediate or high-risk):
- Baseline Pt >200,000: Initially PO 20mg BD *4/52, then may increase dose by 10mg/day no more frequently than every 2 weeks to a max 25mg BD
-
- Baseline Pt 100,000-200,000: Initially PO 15mg BD *4/52, then may increase dose by 10mg/day no more frequently than every 2 weeks to a max 25mg BD
-
- Baseline Pt 50,000-99,000: PO 5mg BD *4/52, then may increase dose by 5mg/day no more frequently than every 2 weeks to a max 10mg BD
- Baseline Pt 50,000-99,000: PO 5mg BD *4/52, then may increase dose by 5mg/day no more frequently than every 2 weeks to a max 10mg BD
- Polycythemia vera:
- Initially PO 10mg BD *4/52, then may increase dose by 10mg/day no more frequently than every 2 weeks to a max 25mg BD
- For hydroxyurea-refractory or intolerant disease
- Acute graft versus host disease (GVHD) for steroid-refractory disease:
- Adults and ≥12 years: PO 5mg BD for at least 3 days, then may increase dose to 10mg BD
- Adults and ≥12 years: PO 5mg BD for at least 3 days, then may increase dose to 10mg BD
- Chronic graft versus host disease (GVHD):
- Adults and ≥12 years: PO 10mg BD
- Tablet:
- 5mg
- 10mg
- 15mg
- 20mg
- 25mg
- Taken without regard to food
- Can also be given via an NG tube
Kinase inhibitor
It inhibits janus-associated kinases (JAK) 1 and 2, leading to disruption of cytokine and growth factor signaling pathways
- Infection
- Dizziness
- Dyspnea
- Hemorrhage
- Edema
- Diarrhea
- Fatigue
- Hypertension
- Headache
- Ecchymosis
- Musculoskeletal pain
- Nausea
- Fever
- Cough
- UTI
- Thrombosis
- Weight gain
- Rash
- Muscle spasms
- Anemia
- Thrombocytopenia
- Hypercholesterolemia
- Elevated ALT/AST
- Neutropenia
- Hypersensitivity to components
- CrCl <15 (patients not on hemodialysis)
- Hepatic impairment with platelets <50,000
- Active infection
- Breastfeeding during treatment and for 2 weeks after discontinuation
- Abrupt withdrawal
- Live vaccines
Drug Status
Availability | Prescription only |
Pregnancy | Category C |
Breastfeeding | Contraindicated |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Jakavi | 5mg | Tablet | 14’s | Novartis Kenya | Novartis Kenya |
Jakavi | 15mg | Tablet | 14’s | Novartis Kenya | Novartis Kenya |
Jakavi | 20mg | Tablet | 14’s | Novartis Kenya | Novartis Kenya |